Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zensun (Shanghai) Science & Technology Co. Ltd.

www.zensun.com

Latest From Zensun (Shanghai) Science & Technology Co. Ltd.

Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

China Investment Roundup: Active Deal-Making In Precision Medicine

Winter is coming, yet China’s financial market is still hot for healthcare companies looking at a prosperous period of investment before the year ends. Capital investments from Chinese investors dramatically increased in November, particularly in the precision medicines segment. Although Chinese Creat Group’s expected record-breaking outbound pharmaceutical acquisition deal worth $1.5bn failed to gain US approval, cross-border M&A remained active.

China Commercial

Soligenix data-enriched by China mucositis deal with SciClone

As part of a strategy to focus solely on developing its Chinese commercial business, the US firm SciClone Pharmaceuticals has signed its third licensing deal in the past three months, this time acquiring rights in China to Soligenix' innate defense regulator for oral mucositis SGX942.

Gastrointestinal Cardiovascular

Deals Shaping The Medical Industry, July 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Zensun (Shanghai) Science & Technology Co. Ltd.
  • Senior Management
  • Mingdong Zhou, PhD, CEO & CSO
    Joseph Hansen, CFO
    Zhenggang Jiang, PhD, VP, Bus. Dev.
  • Contact Info
  • Zensun (Shanghai) Science & Technology Co. Ltd.
    Phone: 21 5080 2627
    68 Ju LI Rd.
    Shanghai, 201203
    China
UsernamePublicRestriction

Register